PARP Inhibitor Market is projected to expand substantially, surpassing USD 16,153.50 million by 2034 at a CAGR of 8.70%.

A resurgence in mergers and acquisitions dealmaking is turbocharging the market for the safest US corporate debt to its ...

AbbVie announced positive topline results from its Phase III TEMPO-1 trial for tavapadon as a monotherapy for early Parkinson ...

AbbVie ABBV has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual ...

This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...

Revance's merger with Crown Labs boosts shares, but stability concerns remain. See more about RVNC stock and why ongoing ...

Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...

The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of ...

Biomea Fusion said on Thursday the U.S. Food and Drug Administration lifted a clinical hold on ongoing studies of its ...

NORTH CHICAGO, IL, USA I6, 2024 I AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-1 trial for ...

AbbVie Inc (NYSE:ABBV) released topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in ...

The trial studied two doses of the drug, tavapadon, as a monotherapy in which patients showed a statistically significant ...